Financial Data and Key Metrics Changes - Revenue for 2025 increased by 20% to approximately $2.2 million, compared to $1.86 million in 2024. Excluding a temporary revenue impact from the transition to managing Amazon sales, full-year revenue growth would have been closer to 30% [6][10] - Gross margin improved to 62.5% in 2025 from 54.1% in 2024, reflecting an improved product mix and a growing contribution from e-commerce channels [10] - The company reported a net loss of $6.4 million in 2025, compared to a net loss of $6.2 million in 2024. Adjusted net loss for the year would have been approximately $5.6 million when excluding one-time legal expenses [10][11] Business Line Data and Key Metrics Changes - E-commerce revenue increased by 88% in 2025, driven by strong growth on Amazon and the direct-to-consumer website, now representing more than half of total revenue [8] - Municipal markets are seeing increased interest in fertility control approaches, with ongoing programs in cities like New York and Chicago [8][9] Market Data and Key Metrics Changes - Internationally, the company expanded its footprint with regulatory approvals in New Zealand and new distribution relationships in Belize [9] - The company is in discussions with potential deployment partners in New York City as the trial of Evolve concludes [9] Company Strategy and Development Direction - The company's core strategy remains focused on scaling current initiatives and maintaining resource allocation discipline while searching for a new CEO [5] - The company aims to accelerate growth in e-commerce, municipal adoption, and technology validation while managing operating expenses carefully [11] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for growth in 2026, aiming for higher revenue growth rates than in 2025 [13] - The company is focused on maintaining financial discipline while investing in areas with traction, such as e-commerce and municipal markets [11] Other Important Information - The legal dispute with Liphatech has been resolved satisfactorily, with all litigation dismissed [10][22] - The company ended 2025 with $8.6 million in cash and short-term investments, providing a solid operating runway [11] Q&A Session Summary Question: Should we expect similar growth rates in 2026 as in 2025? - Management indicated that growth could be higher, aiming to accelerate growth in profitable areas [13] Question: What will contribute to 2026 revenues? - Revenue will come from a mix of e-commerce, municipal orders, and international expansion [14][15] Question: What is the status of the court case with Liphatech? - The case has been settled satisfactorily, and the company does not expect recurring legal costs related to this issue [22][23] Question: What is the status of product registration in Australia? - Regulatory authorities are expected to provide a response in the spring regarding product registration [25] Question: Will the new CEO have incentives based on stock performance? - Yes, a meaningful portion of the CEO's compensation is expected to be equity-based and aligned with long-term shareholder value [56] Question: How is the agricultural sector performing? - The agricultural sector is performing well, with expansions in various areas including almond groves and poultry [33] Question: Will the company expand its sales team? - Yes, the company plans to expand its sales team to maximize B2B sales efforts [60]

Financial Data and Key Metrics Changes - Revenue for 2025 increased by 20% to approximately $2.2 million, compared to $1.86 million in 2024. Excluding a temporary revenue impact from the transition to managing Amazon sales, full-year revenue growth would have been closer to 30% [6][10] - Gross margin improved to 62.5% from 54.1% in 2024, reflecting an improved product mix and a growing contribution from e-commerce channels [10] - The company reported a net loss of $6.4 million for 2025, compared to a net loss of $6.2 million in 2024. Adjusted net loss would have been approximately $5.6 million when excluding one-time legal expenses [10][11] - Adjusted EBITDA loss improved to $5.3 million compared to $5.8 million in 2024 [11] - The company ended the year with $8.6 million in cash and short-term investments, providing a solid operating runway [11] Business Line Data and Key Metrics Changes - E-commerce revenue increased by 88%, driven by strong growth on Amazon and the direct-to-consumer website, now representing more than half of total revenue [8] - Municipal markets are seeing increased interest in fertility control approaches, with ongoing programs in cities like New York and Chicago [8][9] Market Data and Key Metrics Changes - Internationally, the company expanded its footprint with regulatory approvals in New Zealand and distribution relationships in Belize [9] - The company is in discussions with potential deployment partners in New York City as the trial of Evolve concludes [9] Company Strategy and Development Direction - The company's core strategy remains focused on scaling current initiatives and maintaining resource allocation discipline [5] - The board is engaged in finding a new CEO to help scale the business and build on progress made [5] - The company aims to maintain financial discipline while investing in areas with traction, including e-commerce and municipal adoption [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about accelerating growth in 2026, particularly in e-commerce and municipal markets [13][15] - The company is focused on maximizing growth while ensuring profitability [13] - Management is confident in the potential for improvement in financial performance and is preparing for increased demand [45][46] Other Important Information - The legal dispute with Liphatech has been resolved satisfactorily, with all litigation dismissed [10][22] - The company is preparing for a significant year ahead, with expectations for growth in various markets [72] Q&A Session Summary Question: Should we expect similar growth rates in 2026 as in 2025? - Management aims for higher growth rates, particularly in areas where they can maximize profitability [13] Question: What will contribute to 2026 revenues? - Revenue will come from a mix of e-commerce, municipal orders, and international expansion [15] Question: What is the status of the court case with Liphatech? - The case has been settled satisfactorily, and the company considers it a past issue [22] Question: What is the status of product registration in Australia? - Regulatory authorities are expected to provide a response in the spring [25] Question: Will the new CEO have incentives based on stock performance? - Yes, a meaningful portion of the CEO's compensation will be equity-based and aligned with long-term shareholder value [56] Question: How is the agricultural sector performing? - The agricultural sector is expanding, with successes noted in almond groves and poultry [33] Question: Will the company expand its sales team? - Yes, the company plans to expand its sales team to maximize B2B sales efforts [60]

Financial Data and Key Metrics Changes - Revenue for 2025 increased by 20% to approximately $2.2 million, compared to $1.86 million in 2024. Excluding a temporary revenue impact from transitioning to direct management of Amazon sales, full-year revenue growth would have been closer to 30% [6][10] - Gross margin improved to 62.5% from 54.1% in 2024, reflecting an improved product mix and a growing contribution from e-commerce channels [10] - The company reported a net loss of $6.4 million for 2025, compared to a net loss of $6.2 million in 2024. Adjusted net loss for the year would have been approximately $5.6 million when excluding one-time legal expenses [10][11] - Adjusted EBITDA loss improved to $5.3 million compared to $5.8 million in 2024 [11] - The company ended the year with $8.6 million in cash and short-term investments, providing a solid operating runway [11] Business Line Data and Key Metrics Changes - E-commerce revenue increased by 88%, driven by strong growth on Amazon and the direct-to-consumer website, now representing more than half of total revenue [7][8] - Municipal markets are seeing increased interest in fertility control approaches, with ongoing programs in cities like New York and Chicago [8][9] Market Data and Key Metrics Changes - Internationally, the company expanded its footprint with regulatory approvals in New Zealand and new distribution relationships in Belize [9] - The company is in discussions with potential deployment partners in New York City as the trial of Evolve concludes [9] Company Strategy and Development Direction - The company's core strategy remains focused on delivering current initiatives, scaling areas with traction, and maintaining resource allocation discipline [5] - The board is engaged in finding a new CEO to help scale the business and build on progress made [4][5] - The company aims to maintain financial discipline while investing in areas with traction, including e-commerce expansion and municipal adoption [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about accelerating growth in 2026, aiming for higher growth rates than 2025 [13] - The company is focused on a mixture of revenue contributors, including e-commerce, municipal orders, and international expansion [15][17] - Management is confident in the potential for improvement in profitability and revenue growth [45] Other Important Information - The legal dispute with Liphatech has been resolved satisfactorily, with all litigation dismissed [10][22] - The company is preparing for a significant year ahead, with expectations for growth in various markets [74] Q&A Session Summary Question: Should we expect similar growth rates in 2026 as in 2025? - Management indicated that growth could be higher, aiming to accelerate growth in profitable areas [13] Question: What will contribute to 2026 revenues? - A mixture of e-commerce, municipal orders, and international expansion is expected to drive revenue [15] Question: What is the status of the court case with Liphatech? - The case has been settled satisfactorily, and the company considers it a past issue [22] Question: What is the status of product registration in Australia? - Regulatory authorities are expected to provide a response in the spring [25] Question: Will the new CEO have incentives based on stock performance? - Yes, a meaningful portion of the CEO's compensation is expected to be equity-based [56] Question: How is the agricultural sector performing? - The agricultural sector is performing well, with expansions in various areas including almond groves and poultry [33] Question: What municipalities besides New York City are evaluating Evolve? - Baltimore and Chicago are mentioned, with ongoing assessments in various neighborhoods [32] Question: Will the sales team be expanded? - Yes, the company plans to expand the sales team to maximize B2B sales efforts [61]

Core Insights - SenesTech, Inc. reported a 43% increase in revenues to $690,000 for Q3 2025, marking a record for the company, with Evolve® Rodent Birth Control product sales growing 77% year-over-year, now accounting for 85% of total revenue [7][4][1] Financial Highlights - Revenues increased to $690,000 from $482,000 in Q3 2024, representing a 43% growth [7] - Gross profit margin was reported at 62.8% [7] - Net loss for Q3 2025 was $1.3 million, an improvement from a loss of $1.5 million in Q3 2024 [7] - Adjusted EBITDA loss improved to $1.2 million, compared to $1.4 million in the same quarter of the prior year [7] - Cash and short-term investments totaled $10.2 million, providing a solid operating runway [7] Operational and Strategic Highlights - Evolve Rat and Evolve Mouse products, launched in 2024, grew 77% year-over-year and are the largest revenue drivers, representing 85% of total revenue [7] - E-commerce revenue increased by 55% year-over-year, with significant growth in Amazon sales [7] - Municipal revenue grew 139% year-over-year, driven by expanded deployments in cities like New York and Chicago [7] - Retail revenue surged 254% year-over-year, largely due to increased adoption by Ace Hardware and follow-on orders from Bradley Caldwell [7] - Revenue from pest management professionals increased by 29% year-over-year, contributing nearly 20% of overall revenue for Q3 2025 [7]

Core Insights - SenesTech, Inc. will report its third quarter 2025 financial results on November 10, 2025, after market close, followed by a conference call at 5:00 p.m. Eastern time to discuss the results [1][2] Company Overview - SenesTech is focused on humane pest management through fertility control, having developed ContraPest®, the only U.S. EPA-registered contraceptive for both male and female rats, along with Evolve Rat and Evolve Mouse, which are EPA-designated minimum risk contraceptives for rodents [3] Conference Call Details - The conference call on November 10, 2025, will be accessible via a live webcast, with a replay available for 90 days on the company's Investor Relations website [2]

Financial Data and Key Metrics Changes - The company reported a record quarterly revenue increase of 70%, reaching $501,000 for Q4 2024, and a 56% increase in annual revenue to $1.9 million [27][8] - Gross profit margins improved to 61% in Q4 2024, up from 44% in the same quarter last year, with gross profit dollars increasing by 136% [31][8] - The adjusted EBITDA loss was the smallest in company history, with cash burn expected to decrease from $1.5 million to $1 million per quarter [9][34] Business Line Data and Key Metrics Changes - Evolve Rat accounted for 52% of Q4 sales, with a 365% increase compared to the same quarter last year, while Evolve Mouse represented 24% of sales [27][28] - ContraPest sales decreased by 51% as customers transitioned to Evolve solutions [28] Market Data and Key Metrics Changes - E-commerce sales surged by 206% in Q4 2024, representing 55% of total revenue for the quarter [28][29] - The company expanded its distribution agreements in 10 countries, with significant orders from cities like New York and Baltimore [19][15] Company Strategy and Development Direction - The company aims to achieve cash flow breakeven at an annual revenue threshold of $7 million, down from $12 million historically [9] - Strategic financing completed is expected to accelerate progress towards profitability [10][24] - Focus on expanding into municipal markets, warehousing, and international distribution as key growth drivers [22][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's trajectory, highlighting the successful launch of Evolve products and the potential for growth in various markets [11][37] - The company is committed to a focused strategy that emphasizes cost efficiencies and sustainable long-term success [36] Other Important Information - The company is implementing new initiatives to reduce cash burn by $2 million annually and has secured a larger facility to meet increasing demand [9][32] - The introduction of the Lure bait dispenser is expected to enhance product accessibility, although it is not projected to be a high revenue item [53][54] Q&A Session Summary Question: Visibility on New York pilot program - Management indicated that the pilot program in New York will start in April, with potential for expansion based on initial success [42][44] Question: Sales efforts in warehousing and distribution - The company is seeing increased orders from warehousing facilities, particularly in food production, where traditional poisons are not feasible [46][47] Question: E-commerce sales strategy - Management confirmed that advertising and search engine optimization efforts are in place to drive e-commerce sales, with significant growth noted on platforms like Amazon [48][49] Question: Clarification on cash burn reduction - The reduction from $1.5 million to $1 million was clarified as a decrease in cash burn or adjusted EBITDA [50][52] Question: Contribution of Lure bait dispenser - The Lure bait dispenser is seen as a valuable accessory that allows for product use in hard-to-reach areas, generating interest and orders [53][54] Question: Revenue growth from recent contracts - Management noted that regulatory approvals and field trials are necessary before significant revenue contributions can be expected from new contracts [62][64] Question: Traction with big box retailers - The company has seen significant interest from retailers like Ace Hardware, with plans to expand into their warehouses [68][69] Question: Marketing plans for increasing awareness - A comprehensive marketing plan is in place to promote the product's success in municipalities and through social media [71][73] Question: Manufacturing capacity and cost savings - The company has built its supply chain to handle increased demand without constraints, with ongoing efforts to improve manufacturing efficiencies [77][79]